Amyotrophic lateral sclerosis, commonly known as ALS, is a progressive neurodegenerative disease in which the motor neurons that control voluntary movement gradually die, leading to increasing weakness, paralysis, and eventually respiratory failure. Most people survive two to five years after symptoms appear, though the disease varies enormously from person to person. Often called Lou Gehrig’s disease in the United States, ALS is far more complex than a simple “muscle disease,” with cognitive, genetic, and environmental dimensions that researchers are still working to untangle.
How ALS Damages the Body
ALS targets two populations of nerve cells. Upper motor neurons live in the brain and send signals down the spinal cord; lower motor neurons sit in the spinal cord and brainstem and relay those signals out to the muscles. In typical ALS, both sets degenerate simultaneously, though the balance between upper and lower motor neuron damage varies from one person to the next.1PubMed Central. Clinical Spectrum of Amyotrophic Lateral Sclerosis That dual involvement accounts for the characteristic mix of symptoms: muscles waste away and weaken (a lower motor neuron sign) while also becoming stiff and hard to control (an upper motor neuron sign).2PubMed Central. Lower and upper motor neuron involvement and their impact on disease prognosis in amyotrophic lateral sclerosis
At the molecular level, the vast majority of ALS cases share a striking feature: a protein called TDP-43, which normally works inside the nucleus of nerve cells to manage gene activity, migrates out of the nucleus and clumps together in the surrounding cell body. This happens in upward of 95 percent of cases.3PubMed Central. TDP-43-The key to understanding amyotrophic lateral sclerosis The result is a double hit: the clumps themselves are toxic, and the nucleus is left without enough TDP-43 to do its normal job. Research using neurons derived from patients with sporadic ALS has confirmed that the gene-expression changes seen when TDP-43 is artificially removed in labs closely mirror what actually happens in patient cells.4PubMed Central. Sporadic ALS induced pluripotent stem cell derived neurons reveal hallmarks of TDP-43 loss of function Another piece of the puzzle is glutamate excitotoxicity, where excess signaling by the neurotransmitter glutamate overstimulates and damages motor neurons. Several pathways contribute, including dysfunction of the transporter that normally clears glutamate away from synapses and an increase in receptors that let too much calcium into the cell.5PubMed Central. Revisiting Glutamate Excitotoxicity in Amyotrophic Lateral Sclerosis and Age-Related Neurodegeneration
Early Symptoms and Where They Start
ALS does not announce itself the same way in every person. In a study of 500 cases, roughly two-thirds first noticed problems in a limb, about three in ten began with bulbar symptoms (difficulty speaking or swallowing), and a small fraction started with breathing trouble.6PubMed Central. Clinical Course of Amyotrophic Lateral Sclerosis according to Initial Symptoms: An Analysis of 500 Cases Where symptoms begin shapes the whole early experience of the disease.
Limb-onset ALS typically starts with weakness or clumsiness in one hand, foot, or leg. People may notice they are tripping more often, struggling to grip objects, or finding fine movements like buttoning a shirt unexpectedly difficult. Muscle twitches, called fasciculations, are a hallmark early sign across all forms of ALS and can sometimes be detected before obvious weakness sets in.7Brain Communications. The rise and fall of fasciculations in amyotrophic lateral sclerosis These twitches reflect the motor neurons firing erratically as they begin to fail.8PubMed. Amyotrophic lateral sclerosis
Bulbar-onset ALS tends to appear at a slightly older age and begins with slurred speech, difficulty chewing, or choking on food and liquids. Brain imaging studies have found that bulbar-onset disease involves early damage to cortical regions beyond just the motor areas, spreading into frontal and temporal zones, whereas limb-onset ALS initially concentrates its damage more within the primary motor regions themselves.9PubMed Central. Patterns of grey and white matter changes differ between bulbar and limb onset amyotrophic lateral sclerosis Bulbar-onset disease has also been linked more strongly to cognitive and language impairments, with changes seen in brain areas involved in speech and language processing that are not found in limb-onset cases.10PubMed Central. The neuropathological signature of bulbar-onset ALS: A systematic review
Respiratory-onset ALS is the least common form and tends to strike at an even older age. People may first notice breathlessness during mild exertion or while lying flat at night. Because respiratory symptoms are rarely the first thing doctors think to associate with a motor neuron disease, diagnosis can be significantly delayed.
Beyond Muscle Weakness
For decades, ALS was thought of as a purely motor disease, leaving thinking and personality untouched. That view has changed substantially. Cognitive and behavioral changes are now recognized as relatively common, and a portion of people with ALS go on to meet criteria for behavioral variant frontotemporal dementia.11Psychiatry Research Case Reports. Excessive emotional reactivity in a case of behavioral variant frontotemporal dementia with amyotrophic lateral sclerosis Executive function, behavior, and language are the areas most often affected, and screening tools such as verbal fluency tests and caregiver-completed behavioral inventories can help pick up these changes.12PubMed Central. ALS and Frontotemporal Dysfunction: A Review
These cognitive shifts tend to worsen as the disease progresses. A study tracking people across different disease stages found that impairment in ALS-specific cognitive areas, particularly verbal fluency, and rates of behavioral change both climbed with advancing stage. Memory and visual-spatial skills, by contrast, stayed relatively stable.13PubMed Central. ALS-specific cognitive and behavior changes associated with advancing disease stage in ALS For families, this is important to know about early. Personality changes, apathy, and loss of social awareness can strain relationships and complicate caregiving decisions well before the physical decline becomes severe.
What Causes ALS
About 5 to 10 percent of ALS cases run in families. The two most commonly mutated genes are SOD1 and C9orf72.14PubMed. Genetic analysis of the SOD1 and C9ORF72 genes in Hungarian patients with amyotrophic lateral sclerosis The C9orf72 repeat expansion is by far the most frequent genetic cause and has been found in roughly 8 to 9 percent of patients even in those without a known family history.15PubMed Central. Prevalence of SOD1 and C9orf72 Variants Among French ALS Population: The GENIALS Study 16PubMed. Frequency of C9orf72 and SOD1 mutations in 302 sporadic ALS patients from three German ALS centers The fact that these mutations sometimes turn up in “sporadic” cases suggests that the dividing line between familial and non-familial ALS is blurrier than it once seemed, with reduced penetrance meaning some people carry the mutation but never develop symptoms themselves.
For the remaining 90-plus percent of cases with no clear family history, the cause is thought to be a convergence of genetic susceptibility and environmental exposures. Military veterans have been a particularly well-studied group in this regard. Multiple studies have found that veterans face a higher risk of ALS than civilians, and exposure to pesticides, heavy metals, certain chemicals, and head trauma during service appear to contribute.17PubMed Central. Military service and related risk factors for amyotrophic lateral sclerosis Burn pits, engine exhaust, and firing-range exposure have also been flagged as possible neurotoxic factors that may accelerate the disease in susceptible individuals, potentially acting in combination with head injuries.18PubMed Central. A perspective on persistent toxicants in veterans and amyotrophic lateral sclerosis: identifying exposures determining higher ALS risk A recent case-control study found that combat service was associated with roughly two and a half times the odds of developing ALS compared to non-combat military roles.19PubMed Central. Military Service Roles and ALS Among Veterans: A Matched Case-Control Study
The current thinking is a “multistep” model: most people need several risk factors to converge before the disease is triggered. A genetic vulnerability might be one step. An environmental exposure might be another. A head injury, a lifetime of vigorous physical activity, or aging itself could contribute additional steps. No single factor is sufficient for most people, which is why ALS remains relatively rare even among populations with known risk exposures.
Why Diagnosis Takes So Long
There is no single blood test or scan that confirms ALS. Diagnosis remains clinical, meaning doctors piece it together from the pattern of symptoms, the neurological exam, and electrical tests of nerve and muscle function, while ruling out other conditions that can look similar. One important mimic is multifocal motor neuropathy, a rare immune-mediated condition that causes weakness that can closely resemble ALS but, unlike ALS, often responds to treatment.20PubMed Central. The Potential Misdiagnosis of Multifocal Motor Neuropathy as Amyotrophic Lateral Sclerosis-A Case Series Getting this distinction right matters enormously, because a treatable disease can masquerade as an untreatable one.
Diagnostic criteria have evolved over the years to try to balance sensitivity (catching ALS early) with specificity (avoiding false diagnoses). The newer Gold Coast Criteria have shown higher sensitivity than older systems, picking up over 93 percent of ALS cases in one real-world study, but this comes at the cost of lower specificity, meaning more people without ALS may initially meet the criteria.21PubMed Central. Gold Coast Criteria in ALS Diagnosis: A Real-World Experience Despite this progress, the average time from first symptoms to confirmed diagnosis still stretches to about a year for many patients, and longer for those with atypical presentations. That diagnostic delay is one of the most frustrating aspects of the disease for patients and families.
Prognosis and What Shapes It
The often-quoted survival figure of two to five years from symptom onset is a rough average that conceals enormous variation. Some people decline rapidly and die within a year, while others live well beyond a decade. A study that deliberately compared the extremes of this spectrum found that people with very short survival (under 15 months) differed significantly from those with very long survival (over 100 months) in terms of where the disease started, age at onset, body mass at diagnosis, and how quickly function declined.22PubMed. Fast versus slow disease progression in amyotrophic lateral sclerosis-clinical and genetic factors at the edges of the survival spectrum
The rate at which breathing capacity drops is one of the strongest predictors of survival. Patients whose lung function declined more slowly had roughly double the survival time compared to those whose lung function fell quickly.23PubMed. Respiratory systems abnormalities and clinical milestones for patients with amyotrophic lateral sclerosis with emphasis upon survival Respiratory-onset ALS, despite sounding dire, does not always follow a rapidly progressive course. One study found a mean survival of about 27 months from symptom onset, which was comparable to bulbar-onset ALS, and the use of non-invasive ventilation significantly improved survival in that group.24PubMed Central. Prognosis of amyotrophic lateral sclerosis with respiratory onset
There are also slowly progressive subtypes that defy the grim average. A study of people with a particular slowly progressive lower-limb form found a median survival of about 80 months and a five-year survival rate near 80 percent, compared to under 2 percent for typical lower-limb-onset ALS.25PubMed Central. Differentiating Slowly Progressive Subtype of Lower Limb Onset ALS From Typical ALS Depends on the Time of Disease Progression and Phenotype Identifying these slower subtypes early is important because it changes the conversation around prognosis and planning. Stephen Hawking, the most famous example, lived more than 50 years after his diagnosis, though his case was extraordinarily atypical.
Treatments and Their Limits
There is no cure for ALS. The currently approved disease-modifying drugs offer limited benefit, slowing progression only modestly. The recent market withdrawal of one previously approved therapy (AMX0035, marketed as Relyvrio) underscored just how difficult it has been to find effective treatments.26PubMed Central. Current and emerging therapeutic strategies for amyotrophic lateral sclerosis: from pharmacological approaches to gene and stem cell therapies Riluzole, available since the 1990s, remains the longest-standing option and extends survival by a few months on average. Edaravone, another approved drug in some countries, targets oxidative stress but has shown mixed results across different patient populations.
Where management has made a more tangible difference is in supportive care, particularly breathing support. Non-invasive ventilation, essentially a mask-based breathing assist, has been shown in a randomized trial to improve survival by a median of about seven months in patients without severe bulbar impairment, while also maintaining quality of life for most of that added time. For people with severe bulbar dysfunction, ventilation still helped with sleep-related symptoms, though it did not extend survival as clearly.27The Lancet Neurology. Non-invasive ventilation in amyotrophic lateral sclerosis: a randomised controlled trial That survival benefit from ventilation alone is larger than what any neuroprotective drug has achieved to date, which speaks both to the importance of multidisciplinary care and to the limitations of current medications.
Experimental Therapies and Biomarkers
The most promising frontier in ALS treatment is gene-targeted therapy, particularly antisense oligonucleotides, or ASOs. These are short sequences of synthetic DNA designed to dial down the activity of a specific mutant gene. ASOs targeting the two most common ALS genes, SOD1 and C9orf72, have advanced into clinical trials, along with therapies aimed at other genes like FUS and ATXN2.28PubMed Central. Antisense Oligonucleotides for the Study and Treatment of ALS 29PubMed Central. Emerging antisense oligonucleotide and viral therapies for amyotrophic lateral sclerosis The limitation is obvious: these therapies work by targeting specific genetic mutations, so they are relevant only to the minority of patients who carry them. For the 90-plus percent of people with sporadic ALS, gene-targeted treatments are not yet applicable, though the TDP-43 pathway is a shared target that researchers hope could eventually bridge that gap.
Running better clinical trials also requires better ways to measure the disease. Blood levels of a protein called neurofilament light chain (NfL) have emerged as a validated prognostic biomarker. NfL is released when nerve cells are damaged, and higher blood levels correlate with more aggressive disease, faster decline, and shorter survival.30PubMed Central. Neurofilament light chain in drug development for amyotrophic lateral sclerosis: a critical appraisal In a multicentre study, plasma NfL was the only blood-based variable independently associated with shortened survival after accounting for other prognostic factors.31Brain Communications. Multicentre appraisal of amyotrophic lateral sclerosis biofluid biomarkers shows primacy of blood neurofilament light chain ALS patients show dramatically higher NfL levels than healthy individuals, and these levels track with disease duration.32Scientific Reports. Correlation analysis of serum neurofilament light chain and glial fibrillary acidic protein levels with amyotrophic lateral sclerosis Beyond prognosis, NfL could serve as a way to measure whether an experimental drug is actually slowing nerve damage in real time, which would make clinical trials faster and more efficient.
Technology for People Living with ALS
Because ALS progressively takes away the ability to move, speak, and eventually breathe independently, assistive technology plays an increasingly central role as the disease advances. Eye-tracking systems are now the standard communication tool for people who have lost the ability to speak and write. But even eye tracking can fail in the latest stages of the disease, when eye movement control deteriorates.
Brain-computer interfaces represent the next step. In a landmark case, a fully implanted brain-computer interface allowed a patient with late-stage ALS to type at roughly two letters per minute by attempting to move a hand, even though the hand itself could no longer move. The device, consisting of electrodes placed on the brain’s surface and a wireless transmitter implanted under the skin, offered autonomous communication that at times replaced the patient’s eye-tracking system.33PubMed Central. Fully Implanted Brain-Computer Interface in a Locked-In Patient with ALS Two letters per minute sounds painfully slow, but for someone who has lost every other way to express a thought, it can be transformative. Research groups are now working on implantable systems that could reach clinical use more broadly, though medical and ethical questions around surgery in people with a progressive terminal illness remain actively debated.34PubMed Central. Towards clinical application of implantable brain-computer interfaces for people with late-stage ALS: medical and ethical considerations
The Weight on Caregivers
ALS does not happen to one person. The physical, emotional, and financial demands on caregivers are enormous and grow as the disease progresses. Caregiving for someone with ALS involves an escalating set of practical challenges: managing feeding as swallowing deteriorates, assisting with mobility and transfers, operating ventilation equipment, and navigating a healthcare system that often lacks coordinated ALS-specific resources.35PubMed Central. Caregiving in ALS – a mixed methods approach to the study of Burden
Caregiver burden is a well-documented phenomenon in ALS research, encompassing feelings of loss, loneliness, and emotional upheaval alongside the physical exhaustion of round-the-clock care.36PubMed Central. Caregiver burden and associated factors among primary caregivers of patients with ALS in home care: a cross-sectional survey study The cognitive and behavioral changes described earlier add a layer that many caregivers are unprepared for. When the person you are caring for also becomes apathetic, disinhibited, or unable to participate in decisions about their own care, the emotional toll compounds the physical one. Early connection with a multidisciplinary ALS clinic, palliative care team, and caregiver support network does not change the disease trajectory, but it can meaningfully change how the experience is lived on both sides of it.